TRPV channels Market: Competitive Landscape, Pipeline, and Market Analysis 2023

Purchase Option

$ 4000
$ 6600
$ 8900

The Transient Receptor Potential Vanilloid (TRPV) channel is a subfamily of the TRP family of receptors that are animal cation channels. TRPV subfamily has six members – TRPV1, TRPV2, TRPV3, TRPV4, TRPV5, and TRPV6. TRPV1-4 have non-selective cation conducting pores, while TRPV5 & 6 are calcium selective. TRPV1 is highly expressed in sensory neurons and is activated by Capsaicin, Protons, Toxins, and temperature above 42?C. It is physiologically essential for thermal perception and chemical nociception. TRPV2 has been associated with diseases like cancer. TRPV3 is associated with skin health and has gained importance due to it. TRPV4 has osmoregulation and mechano-transduction roles in the body. Both TRPV5 & TRPV6 are present in the apical membrane of the epithelial cells and act as a gateway for Ca2+ during absorption and reabsorption. TRPV5 is highly expressed in the kidney, while TRPV6 is expressed in various organs, including the intestine and placenta. Hence, these receptors play a very crucial role in the physiological roles of our body.  Companies are trying to find new and novel molecules to prevent and cure these diseases. The development and launch of newer products by the market players will significantly enhance the revenue of the TRPV channels market over the forecast years. According to a research article, in 2022, about 3-17% of the population will suffer from Neuropathic pain.

Several of these inhibitors are on the market, while many are in ongoing clinical trials.  companies have various products in their pipelines, with 52 products in various stages of clinical trials. 1 product is in Phase 4, 8 products are in Phase 3, 19 products are in Phase 2, and 5 products are in Phase 1 of the clinical trials.

Key Developments of TRPV channels

  • In May 2023, resiniferatoxin received Breakthrough Therapy designation from the US FDA for treating the pain associated with knee osteoarthritis.
  • In July 2020, Qutenza (8% Capsaicin patch) was approved by the FDA for the treatment of neuropathic pain associated with Diabetic Peripheral Neuropathy (DPN) of the feet in adults.
  • In November 2018, Grunenthal acquired the global commercialization rights for Qutenza from Acorda Therapeutics, Inc (USA).

Clinical Activity and Developments of TRPV Channels

As of June 2023, companies have approximately 52 products for 178 diseases. For these diseases, many trials are being conducted by players globally. For instance,

  • In June 2023, M D Anderson Cancer Center completed a Phase 1 clinical trial to study the tolerability of SOR-C13 –TRPV6 Inhibitor in Patients with Advanced Solid Tumors.
  • In November 2018, Sylentis completed a Phase 3 clinical study to evaluate the safety and efficacy of SYL1001 in patients with moderate to severe Dry Eye Disease.

Approved molecules

  • Qutenza (capsaicin)

 Drugs in Pipeline

  • Adlea (capsaicin)
  • asivatrep (PAC-14028)
  • AZD1386
  • SB-705498
  • resiniferatoxin (MCP-101)
  • vocacapsaicin (CA-008)
  • FLX-787
  • tivanisiran (SYL1001)
  • Civamide nasal spray (zucapsaicin nasal)
  • XEN-D0501
  • bamosiran (SYL040012)
  • Civamide topical (zucapsaicin topical)
  • DWP05195
  • Finalgon (nonivamide/nicoboxil)
  • V-116517
  • resiniferatoxin (MTX-071)
  • ACD440
  • KM-001
  • NEO6860
  • SOR C13
  • capsaicin topical liquid (NGX-1998)
  • libvatrep eye drop (SAF312 eye drops)
  • libvatrep oral (SAF312)
  • 1% capsaicin topical liquid (CGS-200-1)
  • 5% capsaicin topical liquid (CGS-200-5)
  • ABT-102
  • CBP-1008
  • Civamide oral (zucapsaicin)
  • GRC 15300
  • GRC 6211
  • MK-2295
  • parentide (DD04107)
  • phenylcapsaicin

Molecule name

Number of studies

Qutenza (capsaicin)


Adlea (capsaicin)


asivatrep (PAC-14028)








Target Indication Analysis of TRPV Channels

Qutenza (8% Capsaicin), an agonist of  TPRV Channels by Grunenthal, is marketed globally in many markets, including the USA, Europe, Canada, and others. It is indicated for treating neuropathic pain associated with Diabetic Peripheral Neuropathy (DPN) of the feet in adults. It is also in the clinical trials for many other indications like neuropathies, including Diabetic Neuropathy, neuralgia, viral infections, and Peripheral Nerve Injuries in the later stages of the clinical trials. Resiniferatoxin (MCP-101), a potent functional analogue of capsaicin, has been designated a Breakthrough therapy for pain associated with knee osteoarthritis. It is in the 3rd phase of the clinical trial for many indications while also being evaluated for other indications.

Frequently Asked Questions

Qutenza (8% Capsaicin) is approved by the FDA, while resiniferatoxin (MCP-101) has received Breakthrough Therapy designation from the FDA.

These are used in various indications like Peripheral Neuropathic Pain, Peripheral pain associated with osteoarthritis of the knee Diabetic Peripheral Neuropathy, and others.

Grunenthal (Germany), LTS Lohmann Therapy Systems AG (Germany), Arcion Therapeutics Inc (USA), Centrexion Therapeutics (Boston), and Amorepacific Corporation (South Korea) are some of the major market players for TRPV Channels.

Rising incidence of diseases, improvement in technologies, development of new treatment lines in the market, and changing lifestyles leading to Diabetes Mellitus and nerve injuries and associated pain are the key opportunities for TRPV channels in the market.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • Grunenthal (Germany)
  • LTS Lohmann Therapy Systems AG (Germany)
  • Arcion Therapeutics Inc (USA)
  • Centrexion Therapeutics (Boston)
  • Amorepacific Corporation (South Korea)
  • AstraZeneca (USA)
  • GSK plc (UK)
  • Sorrento Therapeutics Inc (USA)
  • Concentric Analgesics, Inc (USA)
  • Salarius Pharma Corporation (USA)
  • PharmaMar (Spain)
  • Winston Pharmaceutical Pvt Ltd (India)
  • Pila Pharma (Sweden)
  • Daewoong Pharmaceutical Pvt Ltd. (South Korea)
  • Boehringer Ingelheim (Germany)
  • Purdue Pharma (USA)
  • Shionogi Inc. (Japan)
  • AlzeCure Pharma AB (Sweden)
  • Kamari Pharma (Israel)
  • AazeinTx, Inc. (Canada)
  • Soricimed Biopharma Inc. (Canada)
  • Acorda Therapeutics Inc. (New York)
  • Novartis (Switzerland)
  • Vizuri Health Sciences, LLC (USA)
  • Propella Therapeutics, Inc (USA)
  • AbbVie Inc. (USA)
  • Coherent Biopharma Co., Ltd. (China)
  • Glenmark Pharmaceuticals Ltd. (India)
  • Eli Lilly and Company (USA)
  • Merck (MSD) (USA)
  • BCNpeptides (Spain)
  • Lubrizol (USA)
  • aXichem AB (Sweden)

Adjacent Markets